24 February 2016 - This filing will add important new clinical data to the current label from two Phase III trials evaluating the safety and efficacy of Avycaz, in combination with metronidazole, for the treatment of complicated intra-abdominal infections, including patients with infections due to ceftazidime-nonsusceptible pathogens.

For more details, go to: http://www.allergan.com/news/news/thomson-reuters/fda-accepts-and-grants-priority-review-for-avycaz